This study is examining the safety and effectiveness of two medications, ketamine and riluzole, in treating patients with treatment resistant major depressive disorder. This study will also examine the effectiveness of an FDA approved drug called lamotrigine in decreasing the potential side effects associated with ketamine.
Topic Depression
Country United States of America
Visit trial
Status
Completed
Results Published
Start date
12 January 2006
End date
09 January 2008
Chance of happening
100%
Phase
Phase IV
Design
Blinded
Type
Interventional
Generation
First
Participants
26
Sex
All
Age
21- 70
Therapy
No
Trial Details
This research proposal will investigate a glutamate-modulating agent, riluzole, in treatment-resistant patients who exhibit an acute, sustained response to a single dose of intravenous (IV) racemic ketamine. Fifty ketamine-responders will be randomized to riluzole or placebo in a 4-week, randomized, double-blind, continuation-phase study.NCT Number NCT00419003
Sponsors & Collaborators
Baylor College of MedicineThis company doesn't have a full profile yet, it is linked to a clinical trial.
National Alliance for Research on Schizophrenia and Depression
This company doesn't have a full profile yet, it is linked to a clinical trial.
National Center for Research Resources
This company doesn't have a full profile yet, it is linked to a clinical trial.
Measures Used
Montgomery-Asberg Depression Rating ScaleA ten-item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders.